PT-141 (Bremelanotide) dosing & administration
The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
1 mg
Frequency
As needed, ~45 min before sexual activity; no more than once per 24 h
Duration
Trial period (assess response/tolerability)
Lower 1 mg trial dose used in practice to gauge nausea tolerance before moving to the FDA dose [6]. Inject into abdomen or thigh.
Timing
Best time to take
Take PT-141 at least 45 minutes before anticipated sexual activity. Effects typically begin within 45-60 minutes and can last several hours. Some people find it works better with 60-90 minutes lead time.
With food?
Taking PT-141 on an empty stomach may increase nausea. A light meal or snack beforehand can help reduce stomach upset without significantly affecting absorption.
If stacking
PT-141 is typically used as a standalone treatment. Its unique mechanism of action through melanocortin receptors means it doesn't directly interact with most other peptides, but consult your healthcare provider before combining with other treatments.
Adjusting your dose
Increase if
- You tolerate the starting dose with minimal nausea
- Effects feel insufficient after multiple tries at current dose
- Your healthcare provider recommends adjustment based on your response
Decrease if
- Nausea is severe or interferes with the experience
- You experience significant blood pressure increases
- Flushing or headaches are uncomfortable
- Side effects outweigh the benefits
Signs of right dose
- Noticeable increase in sexual desire within 1-2 hours
- Manageable or no nausea
- Enhanced arousal response during intimacy
- No significant blood pressure changes
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—this is how the FDA-approved Vyleesi autoinjector delivers the dose
Best sites
Storage
Before reconstitution
Keep your PT-141 powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder remains stable for 2+ years when frozen.
After reconstitution
Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution—freezing destroys the peptide. Keep away from light and use within 30 days. The FDA-approved Vyleesi autoinjector should also be refrigerated.
Signs of degradation — discard the vial
Sample daily schedule
45-60 minutes before anticipated intimacy
1.75 mg (standard FDA-approved dose) injection
Site: Abdomen or thigh
PT-141 is used on-demand, not on a daily schedule. Effects begin within 45-60 minutes and can last several hours. Do not take more than one dose in 24 hours, and limit to 8 doses per month maximum.
Safety
Is it safe?
Side effects
Commonly reported: Nausea, Facial flushing, Headache, Injection site reactions
Less common: Skin darkening (hyperpigmentation)
Stop and seek help if
- Severe nausea that makes the experience unpleasant or affects your health
- Significant blood pressure increases, especially if you feel chest discomfort or severe headache
- Noticeable skin darkening that concerns you (may be irreversible)
- Any signs of allergic reaction—hives, swelling, difficulty breathing
- The medication isn't providing the desired effect after multiple attempts
- You become pregnant or are trying to conceive
PT-141 (Vyleesi) is an FDA-approved medication, but it should be used under healthcare provider supervision. This information is educational—always consult your doctor about starting, stopping, or adjusting any medication. Report any unexpected side effects to your healthcare provider.
Flagged pairings
- Melanotan II — Both act on melanocortin receptors. Combining them increases risk of side effects including nausea, blood pressure changes, and hyperpigmentation. Avoid using together.
- Blood pressure medications — PT-141 affects blood pressure. Combining with antihypertensives may have unpredictable effects. Use only under medical supervision with monitoring.
- Naltrexone — Naltrexone blocks opioid receptors and may reduce PT-141's effectiveness through overlapping neural pathways. Effectiveness may be diminished.
- PDE5 inhibitors (Viagra, Cialis) — Both affect cardiovascular parameters. While sometimes combined in research for ED, this should only be done under medical supervision due to additive effects.
- MAO inhibitors — PT-141 affects dopamine and norepinephrine release. MAOIs can dangerously amplify these effects. Avoid combining.
Published research
What the studies show
Kingsberg SA, Clayton AH, Portman D · 2019
The landmark RECONNECT trials that led to FDA approval. Over 1,200 premenopausal women with HSDD showed statistically significant improvements in sexual desire and reduction in distress compared to placebo. The 1.75mg dose delivered real benefits where it mattered most.
Simon JA, Kingsberg SA, Portman D · 2019
The 52-week extension study showed PT-141 maintained its effectiveness over time without developing tolerance. No new safety signals emerged with long-term use, and improvements in desire and reduced distress persisted throughout.
Dhillon S, Keam SJ · 2019
This comprehensive review covered PT-141's journey from lab to FDA approval. It explained how the drug works on MC4 receptors in the brain's desire circuits—a completely novel mechanism compared to existing sexual health treatments.
Pfaus JG, Sadiq A, Spana C · 2022
Deep dive into how PT-141 actually works in the brain. It activates MC4 receptors in the hypothalamus, triggering dopamine release in areas that control sexual motivation. This explains why it enhances desire itself, not just physical response.
Koochaki P, Revicki D, Wilson H · 2021
Real-world feedback from clinical trial participants. Women reported meaningful improvements in their sexual experiences and quality of life. Most felt the benefits outweighed the side effects, particularly nausea.
AMAG Pharmaceuticals (FDA) · 2019
Head to head
PT-141 (Bremelanotide) compared
Want the full picture?
The complete PT-141 (Bremelanotide) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.